Brokerages Anticipate Galectin Therapeutics Inc. (GALT) to Announce -$0.14 Earnings Per Share

Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to report earnings per share (EPS) of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galectin Therapeutics’ earnings, with estimates ranging from ($0.18) to ($0.10). Galectin Therapeutics posted earnings per share of ($0.11) in the same quarter last year, which would indicate a negative year over year growth rate of 27.3%. The company is scheduled to report its next earnings results on Tuesday, August 13th.

On average, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.75) to ($0.42). For the next financial year, analysts forecast that the firm will report earnings of ($0.62) per share, with EPS estimates ranging from ($0.65) to ($0.58). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.08) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.08).

GALT has been the topic of several analyst reports. ValuEngine downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, B. Riley initiated coverage on Galectin Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $11.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $9.42.

NASDAQ GALT traded down $0.11 during trading hours on Wednesday, reaching $4.55. 181,032 shares of the stock traded hands, compared to its average volume of 366,382. Galectin Therapeutics has a 1 year low of $3.17 and a 1 year high of $9.49.

In related news, Director Marc Rubin sold 51,185 shares of the firm’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $6.02, for a total value of $308,133.70. Following the sale, the director now directly owns 13,581 shares of the company’s stock, valued at $81,757.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard E. Uihlein bought 20,700 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was acquired at an average cost of $4.82 per share, for a total transaction of $99,774.00. Following the completion of the purchase, the director now directly owns 2,628,489 shares of the company’s stock, valued at $12,669,316.98. The disclosure for this purchase can be found here. 45.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of GALT. Wells Fargo & Company MN grew its stake in shares of Galectin Therapeutics by 45.7% in the third quarter. Wells Fargo & Company MN now owns 58,471 shares of the company’s stock worth $352,000 after purchasing an additional 18,336 shares during the last quarter. BlackRock Inc. boosted its position in Galectin Therapeutics by 2.3% during the 3rd quarter. BlackRock Inc. now owns 601,657 shares of the company’s stock valued at $3,616,000 after acquiring an additional 13,349 shares in the last quarter. Vanguard Group Inc. boosted its position in Galectin Therapeutics by 18.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after acquiring an additional 225,822 shares in the last quarter. Vanguard Group Inc boosted its position in Galectin Therapeutics by 18.7% during the 3rd quarter. Vanguard Group Inc now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after acquiring an additional 225,822 shares in the last quarter. Finally, D.A. Davidson & CO. boosted its position in Galectin Therapeutics by 4.3% during the 4th quarter. D.A. Davidson & CO. now owns 718,923 shares of the company’s stock valued at $2,466,000 after acquiring an additional 29,645 shares in the last quarter. 12.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Recommended Story: Index Funds

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.